Health Technology
Shionogi & Co., Ltd.
- 5,761.00 JPY
- -22.00
- -0.38%
Japan
Aug 21, 2019Ticker
TKS(4507)Prev. close
5,783Market cap (JPY)
1,831.97BMarket cap (USD)
17,204.85MShares
316.78M
In the news
- China's big data draws Big Pharma Aug 1, 2019
- Single-dose flu drug approved for sale in Japan Feb 23, 2018
- Takeda Pharma buying Belgian startup TiGenix for $626m Jan 6, 2018
- Pharmaceutical maker Shionogi tapping AI to speed drug development Jan 5, 2018
- Chugai Pharma eyes sale of generics operations to Taiyo Nov 14, 2017 See more articles on Shionogi & Co., Ltd.
Business Summary
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 363,721M | 3,279.87M |
| Gross Profit | 308,841M | 2,784.99M |
| Operating income | 138,538M | 1,249.27M |
| Income before tax | 170,343M | 1,536.07M |
| Net income | 132,759M | 1,197.16M |
| EBITDA | 157,737M | 1,422.40M |
| Diluted EPS | 420.66 | 3.79 |
| Dividends Per Share | 94 | 0.84 |
| Total Assets | 778,741M | 7,035.65M |
| Total liabilities | 106,308M | 960.45M |
| Total equity | 668,029M | 6,035.40M |
| Operating cash flow | 145,684M | 1,313.71M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 273,991M | 309,973M | 338,890M | 344,667M | 363,721M |
| Gross Profit | 191,802M | 235,215M | 261,113M | 270,756M | 308,841M |
| Operating income | 50,365M | 91,406M | 108,179M | 115,219M | 138,538M |
| Income before tax | 82,051M | 97,452M | 122,695M | 137,378M | 170,343M |
| Net income | 44,060M | 66,687M | 83,878M | 108,866M | 132,759M |
| EBITDA | 66,016M | 107,275M | 124,519M | 134,226M | 157,737M |
| Diluted EPS | 132.04 | 201.70 | 255.87 | 337.42 | 420.66 |
| Dividends Per Share | 52 | 62 | 72 | 82 | 94 |
| Total Assets | 602,900M | 639,638M | 670,271M | 711,463M | 778,741M |
| Total liabilities | 124,017M | 125,761M | 144,058M | 106,619M | 106,308M |
| Total equity | 474,530M | 509,792M | 522,737M | 601,374M | 668,029M |
| Operating cash flow | 45,604M | 102,290M | 111,903M | 129,790M | 145,684M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 2,494.08M | 2,581.29M | 3,129.53M | 3,109.80M | 3,279.87M |
| Gross Profit | 1,745.93M | 1,958.74M | 2,411.29M | 2,442.93M | 2,784.99M |
| Operating income | 458.46M | 761.18M | 998.99M | 1,039.57M | 1,249.27M |
| Income before tax | 746.89M | 811.52M | 1,133.04M | 1,239.51M | 1,536.07M |
| Net income | 401.06M | 555.33M | 774.58M | 982.25M | 1,197.16M |
| EBITDA | 600.92M | 893.33M | 1,149.89M | 1,211.07M | 1,422.40M |
| Diluted EPS | 1.20 | 1.67 | 2.36 | 3.04 | 3.79 |
| Dividends Per Share | 0.47 | 0.51 | 0.66 | 0.73 | 0.84 |
| Total Assets | 5,027.30M | 5,690.98M | 6,015.17M | 6,689.82M | 7,035.65M |
| Total liabilities | 1,034.12M | 1,118.91M | 1,292.81M | 1,002.52M | 960.45M |
| Total equity | 3,956.88M | 4,535.71M | 4,691.16M | 5,654.66M | 6,035.40M |
| Operating cash flow | 415.12M | 851.81M | 1,033.38M | 1,171.04M | 1,313.71M |
Valuation Measures
| Mar 2019 | |
| PER | 16.14 |
| ROA | 17.81% |
| ROE | 20.91% |
| Operating margin | 38.08% |
| Profit margin | 36.50% |
Key executives
- President & Representative Director: Isao Teshirogi
- Manager-Accounting & Finance: Kohji Hanasaki
- Director & Vice President: Takuko Sawada
- Executive Officer & Personnel Manager: Noriyuki Kishida
- SVP-Pharmaceutical Research Division: Takeshi Shiota
Shareholders
- Sumitomo Life Insurance Co. (5.8%)
- Nomura Asset Management Co., Ltd. (5.6%)
- Asset Management One Co., Ltd. (4.2%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
- BlackRock Fund Advisors (3.3%)
- Nikko Asset Management Co., Ltd. (3.0%)
- Sumitomo Mitsui Banking Pension Fund (2.9%)
- Nippon Life Insurance Co. (2.6%)
- Daiwa Asset Management Co. Ltd. (2.5%)
- The Vanguard Group, Inc. (2.3%)
Contact Details
- Website:http://www.shionogi.co.jp
- Address: 3-1-8 Dosho-machi, Chuo-Ku, Osaka, 541-0045, Japan
- Phone: +81.6.6202.2161
Related Companies
- Shionogi & Co. Restricted Stock Compensation Plan
- Shionogi Healthcare & Co. Ltd.
- Pionnier KK
- Shionogi USA Holdings, Inc.
- Beijing Shionogi Pharmaceutical Technology Ltd.
- Shionogi Ltd.
- Ezose Sciences, Inc.
- Shionogi, Inc.
- Shionogi Institute for Medical Science
- Aburahi Laboratories
- Taiwan Shionogi & Co. Ltd.
- Shionogi Pharma Chemicals Co., Ltd.
- Shionogi General Service Co., Ltd.
- Shionogi Bunseki Center KK
- Shionogi Ireland Ltd.
- Shionogi Engineering Service Co. Ltd.
- Shionogi Bioresearch Corp.
- Shionogi & Co. Ltd. Pension Fund
- Daiwa Trading Co., Ltd.
- Soei Co., Ltd.
- Tall Bridge, Inc.
- C&O Pharmaceutical Technology (Holdings) Ltd.
- QuatRx Pharmaceuticals Company
- Shionogi Pharma, Inc.
Competitors
- Gilead Sciences, Inc.
- NanoViricides, Inc.
- aTyr Pharma, Inc.
- Vaxart, Inc.
- TaiMed Biologics Inc.
- KemPharm, Inc.
- BioCryst Pharmaceuticals, Inc.
- Iterum Therapeutics Plc
- Achaogen, Inc.
- Dova Pharmaceuticals, Inc.
- Acura Pharmaceuticals, Inc.
- Nektar Therapeutics
- Biohaven Pharmaceutical Holding Company Ltd.
- Entasis Therapeutics Holdings, Inc.
- Nabriva Therapeutics Plc
- Progenics Pharmaceuticals, Inc.
- Spero Therapeutics, Inc.
- Tetraphase Pharmaceuticals, Inc.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 21 Aug, 2019